Urania Dafni

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Nathan I. Cherny, Richard Sullivan, Urania Dafni et al. · Annals of Oncology · 2015 · 792 citations · Full text

Oncology, Clinical Benefit Scale, Anti-cancer Therapies +8

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 696 citations

Interim Analysis, Surgical Oncology, Oncology +8

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Nathan I. Cherny, Urania Dafni, Jan Bogaerts et al. · Annals of Oncology · 2017 · 625 citations · Full text

Clinical Effectiveness, Patient Safety, Clinical Trials +4

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

Breast Oncology, Oncology, Adjuvant Chemotherapy +5

Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon

Helen Gogas, J. Ioannovich, Urania Dafni et al. · New England Journal of Medicine · 2006 · 560 citations